BACKGROUND: The European Heart SCORE model constitutes the basis for national guidelines for primary prevention and treatment of cardiovascular disease (CVD) in several European countries. The model estimates individuals' 10-year CVD mortality risks from age, sex, smoking status, systolic blood pressure, and total cholesterol level. The SCORE model, however, is not mathematically consistent and does not estimate all-cause mortality. Our aim is to modify the SCORE model to allow consistent estimation of both CVD-specific and all-cause mortality. METHODS: Using a competing risk approach, we first re-estimated the cause-specific risk of dying from cardiovascular disease, and secondly we incorporated non-CVD mortality. Finally, non-CVD mortality was allowed to also depend on smoking status, and not only age and sex. From the models, we estimated CVD-specific and all-cause 10-year mortality risk, and the expected residual lifetime together with corresponding expected effects of statin treatment. RESULTS: The modified model provided CVD-specific 10-year mortality risks similar to those of the European Heart SCORE model. Incorporation of non-CVD mortality increased 10-year mortality risks, in particular for older individuals. When non-CVD mortality was assumed unaffected by smoking status, the absolute risk reduction due to statin treatment ranged from 0.0% to 3.5%, whereas the gain in expected residual lifetime ranged from 3 to 11 months. Statin effectiveness increased for non-smokers and declined for smokers, when smoking was allowed to influence non-CVD mortality. CONCLUSION: The modified model provides mathematically consistent estimates of mortality risk and expected residual lifetime together with expected benefits from statin treatment.
BACKGROUND: The European Heart SCORE model constitutes the basis for national guidelines for primary prevention and treatment of cardiovascular disease (CVD) in several European countries. The model estimates individuals' 10-year CVD mortality risks from age, sex, smoking status, systolic blood pressure, and total cholesterol level. The SCORE model, however, is not mathematically consistent and does not estimate all-cause mortality. Our aim is to modify the SCORE model to allow consistent estimation of both CVD-specific and all-cause mortality. METHODS: Using a competing risk approach, we first re-estimated the cause-specific risk of dying from cardiovascular disease, and secondly we incorporated non-CVD mortality. Finally, non-CVD mortality was allowed to also depend on smoking status, and not only age and sex. From the models, we estimated CVD-specific and all-cause 10-year mortality risk, and the expected residual lifetime together with corresponding expected effects of statin treatment. RESULTS: The modified model provided CVD-specific 10-year mortality risks similar to those of the European Heart SCORE model. Incorporation of non-CVD mortality increased 10-year mortality risks, in particular for older individuals. When non-CVD mortality was assumed unaffected by smoking status, the absolute risk reduction due to statin treatment ranged from 0.0% to 3.5%, whereas the gain in expected residual lifetime ranged from 3 to 11 months. Statin effectiveness increased for non-smokers and declined for smokers, when smoking was allowed to influence non-CVD mortality. CONCLUSION: The modified model provides mathematically consistent estimates of mortality risk and expected residual lifetime together with expected benefits from statin treatment.
Authors: Charlotte Gry Harmsen; Ivar Sønbø Kristiansen; Pia Veldt Larsen; Jørgen Nexøe; Henrik Støvring; Dorte Gyrd-Hansen; Jesper Bo Nielsen; Adrian Edwards; Dorte Ejg Jarbøl Journal: Br J Gen Pract Date: 2014-04 Impact factor: 5.386
Authors: Gaurav Gulati; Jenica Upshaw; Benjamin S Wessler; Riley J Brazil; Jason Nelson; David van Klaveren; Christine M Lundquist; Jinny G Park; Hannah McGinnes; Ewout W Steyerberg; Ben Van Calster; David M Kent Journal: Circ Cardiovasc Qual Outcomes Date: 2022-03-31
Authors: Charlotte Gry Harmsen; Dorte Ejg Jarbøl; Jørgen Nexøe; Henrik Støvring; Dorte Gyrd-Hansen; Jesper Bo Nielsen; Adrian Edwards; Ivar Sønbø Kristiansen Journal: BMC Health Serv Res Date: 2013-02-25 Impact factor: 2.655
Authors: Janus Christian Jakobsen; Christian Gluud; Per Winkel; Theis Lange; Jørn Wetterslev Journal: BMC Med Res Methodol Date: 2014-03-04 Impact factor: 4.615